BACKGROUND: Rs11614913 is a polymorphism in hsa-miR-196a2 reported to alter mature microRNA expression and function. This single-nucleotide polymorphism (SNP) was reported to be associated with susceptibility and prognosis of lung cancer. METHODS: In this article, association study was performed to reveal the relation between SNP and response rate or severe toxicity after platinum-based regimen in advanced nonsmall cell lung cancer patients. RESULTS: By screening this polymorphism in 442 Chinese patients with MALDI-TOF Mass Spectrometer, significantly higher occurrence of grade 3 or 4 overall toxicity (P = 0.02) in response to treatment was found in patients with homozygous CC. After stratified analyses, association between rs11614912 and overall toxicity existed, especially in individuals treated with gemcitabine (P = 0.006) or cisplatin (P = 0.008), and in male patients (P = 0.02) or younger patients (P = 0.01). CONCLUSION: Our study confirmed that rs11614913 in hsa-miR-196a2 was associated with severe toxicity in lung cancer patients, and might help to improve individualized therapy in the future.
BACKGROUND:Rs11614913 is a polymorphism in hsa-miR-196a2 reported to alter mature microRNA expression and function. This single-nucleotide polymorphism (SNP) was reported to be associated with susceptibility and prognosis of lung cancer. METHODS: In this article, association study was performed to reveal the relation between SNP and response rate or severe toxicity after platinum-based regimen in advanced nonsmall cell lung cancerpatients. RESULTS: By screening this polymorphism in 442 Chinese patients with MALDI-TOF Mass Spectrometer, significantly higher occurrence of grade 3 or 4 overall toxicity (P = 0.02) in response to treatment was found in patients with homozygous CC. After stratified analyses, association between rs11614912 and overall toxicity existed, especially in individuals treated with gemcitabine (P = 0.006) or cisplatin (P = 0.008), and in male patients (P = 0.02) or younger patients (P = 0.01). CONCLUSION: Our study confirmed that rs11614913 in hsa-miR-196a2 was associated with severe toxicity in lung cancerpatients, and might help to improve individualized therapy in the future.
Authors: R Luthra; R R Singh; M G Luthra; Y X Li; C Hannah; A M Romans; B A Barkoh; S S Chen; J Ensor; D M Maru; R R Broaddus; A Rashid; C T Albarracin Journal: Oncogene Date: 2008-07-28 Impact factor: 9.867
Authors: Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris Journal: Cancer Cell Date: 2006-03 Impact factor: 31.743
Authors: Anna E Szafranska; Martina Doleshal; Hayward S Edmunds; Stuart Gordon; Jutta Luttges; Johanna B Munding; Richard J Barth; Edward J Gutmann; Arief A Suriawinata; J Marc Pipas; Andrea Tannapfel; Murray Korc; Stephan A Hahn; Emmanuel Labourier; Gregory J Tsongalis Journal: Clin Chem Date: 2008-08-21 Impact factor: 8.327
Authors: Jin Wang; Jinyun Chen; Ping Chang; Aimee LeBlanc; Donghui Li; James L Abbruzzesse; Marsha L Frazier; Ann M Killary; Subrata Sen Journal: Cancer Prev Res (Phila) Date: 2009-09-01
Authors: Mu-Peng Li; Yao-Dong Hu; Xiao-Lei Hu; Yan-Jiao Zhang; Yong-Long Yang; Chun Jiang; Jie Tang; Xiao-Ping Chen Journal: Int J Environ Res Public Health Date: 2016-11-08 Impact factor: 3.390